GlassScriptPhysician profile
Michael J Kucenic
NPI 1871705699
$2,757.40
in general payments reported to CMS, 2019-2025
27 companies · $143 in 2025
The $143 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,380 · 2020: $489 · 2021: $242 · 2022: $145 · 2023: $114 · 2024: $245 · 2025: $143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $501.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $501.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $500.87 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $355.28 | 2019-2025 | |
| Prugen, INC. Pharmaceuticals | $212.41 | 2019-2020 | |
| Janssen Biotech, INC. | $168.93 | 2020-2025 | Tremfya |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $133.43 | 2019-2020 | |
| Pfizer INC. | $128.11 | 2019-2024 | |
| Genentech USA, INC. | $121.49 | 2019-2022 | |
| Lilly USA, LLC | $117.90 | 2019-2024 | Taltz, Olumiant |
| Regeneron Healthcare Solutions, INC. | $107.33 | 2019-2020 | |
| Leo Pharma INC. | $103.11 | 2019-2024 | Adbry |
| Ucb, INC. | $91.18 | 2019-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $81.23 | 2019-2020 | |
| Dusa Pharmaceuticals, INC. | $80.32 | 2019 | |
| Almirall LLC | $75.63 | 2021-2024 | Seysara |
| Dermavant Sciences, INC. | $68.17 | 2023-2024 | Vtama |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $59.95 | 2019-2020 | |
| Genzyme Corporation | $52.46 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $50.75 | 2023-2024 | Sotyktu |
| Amgen INC. | $49.00 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $38.76 | 2019 | |
| Sandoz INC. | $29.72 | 2019 | |
| Arcutis Biotherapeutics, INC. | $29.68 | 2024-2025 | Zoryve |
| Helsinn Therapeutics (U.S.), INC. | $29.44 | 2019 | |
| Krystal Biotech INC | $21.89 | 2024 | Vyjuvek |
| Integra Lifesciences Corporation | $20.21 | 2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Journey Medical Corporation | $15.25 | 2019 | |
| Biofrontera INC. | $14.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Kucenic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.